11094435908632364994308624

  Rare Revolution Magazine
  • Home
  • Rare Revolutionaries
    • Our Charity Partners
    • Revolutionaries Community
    • Join the Rare Revolution - Charities sign-up
    • Our Corporate Friends
  • Blog
  • Back Issues
  • #RareYouthProject
    • RYP Blog
  • The People of RARE
    • CEO Series
    • PEO Series
  • APP & Downloads
  • Media

CEO
​Series

Maria Picone of TREND Community

1/5/2020

0 Comments

 
Picture
Picture
Motivated by her daughter's diagnosis of a rare disease, Maria Picone and her husband, drew on their extensive experience in clinical research and technology to found TREND Community. Using technology to harness data from social media they are turning anecdotes into real world data, to accelerate research into new treatments and to improve the quality of life for the rare disease community
​
CEO Series: meeting the beating hearts behind the RARE brands
1.
What made you want to move into the wide world of rare disease, and then specifically in the founding of TREND Community and what did that journey look like?
​My husband, Chris, and I were thrust into the world of rare disease when our daughter was born in 2012. After a perfectly normal pregnancy and almost normal delivery she arrived via emergency caesarean section. The moments and days following were confusing, emotional, and the most frightening of our lives. At 10 days she was diagnosed with Prader-Willi syndrome (PWS); that same day we were discharged from the hospital and took her home.

In our previous life (that screeched to a halt 10 days prior) we were entrepreneurs. We had started a digital health company together in 2007 building clinical trial platforms, registries, and other software for pharma, biotech companies, research organisations, and hospitals. The year before our daughter arrived, we also co-founded an analytics start-up with three other founders. Together, Chris and I accumulated nearly 20 years of experience in clinical research and technology which would serve us well in this new chapter of our lives.
​
TREND was inspired by our personal journey. Along with her diagnosis, our doctors delivered the terrible news that our daughter would have severe learning disabilities, battle obesity, and suffer her entire life from an insatiable hunger known as hyperphagia. We were devastated. I spent the next three months scouring the literature which only confirmed what the doctors had told us.
​
Then I joined a private Facebook group of other parents caring for children with PWS and guess what? These kids were thriving. There was an absence of approved drugs—their parents were experimenting with diet, supplements, and off-label and experimental drugs. Clearly some of it was working. So, Chris and I set out to use the technology we’d built for our clients to systematically collect the anecdotes from our new community in order to understand what was working, why was it working, and why some things were working for some kids but not for others. 
2.
Picture
​​​Maria with her husband, Chris
What do you anticipate will be the biggest challenges and opportunities for your
organisation in the next two years?
We quickly realised that collecting data the traditional way was hard, but we’d uncovered insights that would turn out to be life-changing for our daughter and for others too. What if we could just pull the data right out of the conversations we were having with one another on our private social network? The passing of the 21st Cures Act in 2016 highlighted FDA’s commitment to incorporate patient voices into medical product development and regulatory decision-making. This was just the motivation we needed to take a chance on our innovative idea. Along with our team, Chris and I began developing AI to analyse patient and caregiver conversations on social media to understand disease burden, what people were doing to manage their disease, and their unmet needs.
​
​This new model has opened up a world of opportunities, but also presents many new challenges. In the next couple of years, I believe TREND data will play a key role in bringing more treatments to more patient communities. Our biggest challenge lies in navigating this grey space of unregulated mobile health research. We are following the evolving data protection and privacy regulations, consulting with domain experts such as lawyers and ethicists, and developing guiding principles and a governance structure to ensure that everything we do is for the good of our communities. 
3.
What is your proudest moment in your career thus far?
​Although this has turned into something so much bigger than our family, we began this journey to help our daughter. The knowledge we gained from analysing the social data from our own community and the work that has come out of that helped us to recognise that our daughter was experiencing symptoms of narcolepsy and cataplexy on top of PWS. Last summer she received a medical diagnosis of narcolepsy and now has treatment options that were not previously available to her. And now that she can manage her daytime sleepiness she is thriving in school. As her mom, every day I wake up thinking “How can I make her life even just a little easier?” I am so proud that the company and technology we have poured our hearts and souls into is already having such a meaningful impact on her life and the lives of others in desperate need of treatment options.
4.
What and who are your personal and professional inspirations and why?
I am personally inspired by the people I meet every day who are battling the unthinkable and do so with such bravery and determination to live better lives. There are so many. I couldn’t possibly pick just one.
​
Professionally, I am inspired by Dr. Janet Woodcock. Dr. Woodcock is the Director of the Center for Drug Evaluation and Research at FDA. She is also a vocal advocate for medical innovations that will benefit patients, especially those with unmet medical needs.
Picture
Maria interviewing Dr. Janet Woodcock
5.
What advice would you give someone considering working in the rare disease space?
It’s incredibly rewarding, but it’s also emotionally heavy. We tell this to everyone we hire. It’s important to have people to talk to, a shoulder to cry on. It’s not just a job. I think it inevitably becomes a mission for everyone.
6.
Do you think the government does enough for the rare disease community at a local and central level, and what gaps do you see currently or emerging?
​I am encouraged by what I see from my perspective. Although there’s a lot of red tape, there are also a lot of doors to knock on. There are people at FDA who truly want to improve the lives of patients. I think, however, that there is still a pretty big communication gap. There is the patient-focused side of FDA, tirelessly working to listen to as many patients and caregivers as possible and understand their needs. Then there are the reviewers who are responsible for approving new therapies. We must get everyone around the table to talk about what is possible so that sponsors can propose trial designs that both work for the patient and are acceptable to the agency.
7.
What would you say are some of the biggest motivators for your employees? 
​All of our employees are encouraged by the meaningful nature of the work they do. Interacting with patients and caregivers is a source of constant inspiration. 
8.
What are the toughest parts of being a CEO within TREND, and conversely what are the most rewarding? 
​I think I’ve covered the most rewarding aspects of the job. The toughest part for me has been making sure that I am not only making decisions with my heart. I want to help my daughter. I want to help others. But, we can only do this if we build a successful and sustainable company and sometimes that means making really difficult decisions.
Picture
The definition of multi-tasking! Maria giving a talk with her young son on her hip
9.
What would be your one wish for TREND for the year ahead?
​I hope that in the year ahead we make at least one new discovery that has a profound impact on at least one of our communities.
10.
If you weren’t CEO of TREND what was Plan B?  What did your 10-year-old Maria want to do as a job?
​I majored in psychology in college. My 10-year old self wanted to help people, but she never fathomed that this is how she would be doing it.
Picture
To find out more about the work of TREND Community please visit
www.trend.community
0 Comments

Kimberly Haugstad of Global Genes

30/4/2020

0 Comments

 
Picture
Picture
​While fairly new to the role of CEO of Global Genes, having joined them in September of 2019, Kimberly Haugstad is certainly not new to the world of rare disease having been CEO of The Hemophilia Federation of America for 11 years. Kimberly talks about her personal and professional journey with RARE and her hopes for Global Genes in the coming years

CEO Series: meeting the beating hearts behind the RARE brands
1.
What made you want to move into the wide world of rare disease, and then specifically Global Genes, and what did that journey look like?  ​
My original why is my son. I have a child with severe haemophilia, and so entered the rare disease space about 13 years ago. I started volunteering because I was really interested in what the future held for my son. At that point in the US, there were lifetime caps on pre-existing conditions and the Affordable Care Act hadn't passed and we had some real challenges with my son’s medication. My husband and I were looking at which one of us needed to make a major job change to get a new insurance plan because we had about two years left before we'd hit our cap.
The Hemophilia Federation of America approached me about coming on board as their CEO and helping them really build out the organisation. I thought, "Well, maybe I'll give this a try for a short period of time." I was there for 11 years in the end, but what happens in rare is you fall in love beyond your child. You fall in love with the other
families who are going through the same stages you have been through, or the adult heroes willing to participate in new clinical trials to get drugs to market that would benefit my child. It is really compelling. 

The sort of endurance, resilience and tenacity, and the ability of rare patients to just survive is utterly inspiring every day.
​

I was then approached by a recruiter who introduced me to Global Genes. I knew in the next one to three years I was probably going to leave haemophilia for my own professional growth but I wasn't yet looking. However, I learned more about the organisation, and I caught the bug! To be able to be a part of this broader journey of people globally, in an organisation very similar to the one I came from where the focus truly is on the patient, in a safe space, is so rewarding.
2.
What do you anticipate will be the biggest challenges and opportunities for your organisation in the next two years?  ​
 I think opportunity and challenge both lie with partnerships. I think that we have so much potential in rare right now. There's a great deal of opportunity, and frankly, a lot of interest. We are obligated to take this on and go hard and go fast.
​

We need to build awareness as an organisation. It is really important to be accessible everywhere, but we don't need to do everything ourselves. Sometimes there are people who feel competitive and I'd really like to break that down and role model how partnerships are an opportunity, the way we can operate to achieve the greatest good. We want to demonstrate that you can still be you as an organisation but by partnering you exponentially grow your reach. We are Global Genes—we need to be global. In order to truly scale, it is imperative that we have partnerships. If you see someone doing something really great, join them, celebrate them, promote them
3.
What is your proudest moment in your career thus far?  ​
I am still so new at Global Genes, I think right now it's a haemophilia moment for me. A couple of years ago, we were approached by The AIDS Grove in San Francisco. The AIDS Grove is an area of parkland in the Golden Gate Park in San Francisco, given to the AIDS community to serve as a memorial. The AIDS Grove had come to understand, that in the world of AIDS, haemophilia was not well represented in The Grove. The haemophilia story in the AIDS narrative is incredibly powerful and really helped drive the movement towards really recognising and understanding the disease and ultimately having therapies.

We worked with The Grove, and it was an incredibly beautiful moment when the Hemophilia Memorial was unveiled. It is absolutely marvellous, it is the most beautiful park, and having the opportunity to have haemophilia remembered was so important. To not be forgotten in that greater narrative is so powerful.
​
This then led to us connect with the curator of science and medicine at the Smithsonian, the national American history museum in Washington, D.C., and we made multiple donations of patient haemophilia artefacts. This means the historical remembrance of the haemophilia story, which for me is very important because of my son, will never be forgotten. It feels incredibly powerful that we've been able to accomplish both the visual memorial and the documentation of the archival memorial. Those are my proud little moments.
Picture
Picture
Picture
The beautiful hemophilia memorial in the AIDS Grove
4.
What and who are your personal and professional inspirations and why?  ​
I would always say my son who faces his pain with a fierce and conquering attitude. I would also say strong women. I don't want to pick any one woman. I so admire and am inspired by strong women who aren't afraid to keep pushing to make things happen.
5.
What advice would you give someone considering working in the rare disease space?  ​
I would say that someone coming into the rare disease space ought to listen first. There is a lot happening and duplication of efforts may not be necessary. Do their research, really look at the landscape, and do not be afraid to partner. Sometimes the best way to make an impact quickly is to jump in and help make something already underway stronger with your support, versus always starting something new.
6.
Do you think the government does enough for the rare disease community at a local and central level, and what gaps do you see currently or emerging?  ​
No. Where do I start? Firstly, these ultra-rare and rare conditions are different. It can take so much longer to get diagnosed, and getting care, regardless of what country you live in, when you're undiagnosed, is an incredible challenge. People can get caught in limbo. In the U.S. it's also an issue getting access to medications based on our complicated healthcare system. If there is a drug that would potentially work for you but you're undiagnosed, then potentially your insurance company may not pay for it or you may need to appeal a decision and be forced to petition multiple times to get an exception. The stress and financial impact to patients is incredibly deep and frustrating.
For example, haemophilia is very expensive and I have seen multiple instances where insurance companies and the U.S. government’s Medicaid system advise parents, "What you really need to do here is get a divorce and one of you quit your job. Because then mommy or daddy, whichever one doesn't work, might qualify for Medicaid. You’ll need to live in poverty but your child may be able to get his medicine." I’m using my haemophilia example here but
insert new disease and it’s the same. The healthcare system simply isn’t built for rare or chronic disease, so families are forced into stressful and limiting workarounds to obtain life-saving treatment. It is crazy but it's real.
7.
What would you say are some of the biggest motivators for your employees?   ​
It never ceases to amaze me how small but mighty the teams behind charities are. I think people just assume that there are these massive teams of 70-100 people in an office. I think every one of our team members is ten people in one. They are amazing. A conference such as the Global Genes RARE Patient Advocacy Summit provides inspiration that carries through the rest of the year!
​

Everyone that works for us, regardless of their connection to rare disease, has a passion and came to us looking to work for an organisation that allowed them to contribute something to the community, to the world around them. 
We might not be doctors saving lives, but we can help deliver a message and drive change. And it’s great to see families meet each other. They might meet the first person they have ever spoken to with their same disease and seeing that happen is beautiful.
Picture
Kimberly with our Editor, Nicola Miller, at Global Genes Rare Patient Advocacy Summit, September 2019 ​
8.
What are the toughest parts of being a CEO, and conversely what are the most rewarding?   ​
I think the toughest thing is deciding what you can't do. There are only so many hours in a day, and the team here is less than 30, so there are many opportunities that we just can't get to yet. But I think that's the opportunity, too. All that untapped exciting possibility!
9.
What would be your one wish for Global Genes for the year ahead?  ​
I am really excited about our expanding scope and commitment to broaden our reach to all families living with rare disease wherever they may live. Rare is everywhere and there are rural families, urban families, isolated families living in countries around the world, people from every walk of life that need support and we are dedicated to being here for them. This takes a team but also technology and innovative strategies and partnerships which we are solidifying now to be the inclusive organisation that brings rare together.
10.
If you weren’t CEO of Global Genes, what was Plan B? What did your 10-year-old self want to do as a job?    ​
Picture
If I wasn't here, I had a plan to do something entrepreneurial. Before my son was diagnosed, I worked in technology, and then I worked in the investment world for a while and had my own consulting company. I grew up with strong female role models that always set the expectation that a woman does what she needs and wants to and so my 10-year-old self definitely had big ideas and they all were about being in charge of something. I never envisioned I would end up so closely tied to health, health equity, research, science or technology but it is exactly where I need to be and what I absolutely love.
Picture
To find out more about the work of Global Genes please visit
​www.globalgenes.org
0 Comments

Karim Smaira of Genpharm

28/4/2020

0 Comments

 
Picture
Picture
Meet the CEO shining a light on rare disease in the Middle East. Karim Smaira is the co-founder of pharmaceutical and market access consultancy Genpharm. He talks to RARE Revolution about the importance of putting the patient first and his aspirations for MENA (Middle East and North Africa) patients in the future
​
CEO Series: meeting the beating hearts behind the RARE brands
1.
What made you want to move into the wide world of rare disease, and then specifically in the founding of Genpharm and what did that journey look like?
We live in a region where a strong sense of tradition and cultural heritage co-exist with modernity. As a result, despite the increase in general awareness, Middle Eastern societies still witness high rates of consanguineous marriages, leading to a higher prevalence of inherited and genetic diseases, compared to other parts of the world. While we were exploring the pharmaceutical landscape, it quickly became clear that the level of research and development investments and the number of clinical programs in rare diseases, were going to produce a significant amount of innovations and breakthrough therapies. Moreover, this segment was underserved in the area. The combination of these factors led to establishing Genpharm with a focus on Rare Diseases. 
2.
What do you anticipate will be the biggest challenges and opportunities for your organisation in the next two years?
​The markets we cover are very dynamic and are maturing extremely fast. We have to remain agile and up to date to be able to anticipate or adapt to the current trends both globally and locally. There are significant changes in the landscape particularly in regulatory, market access, pricing and reimbursement. The biggest challenges are certainly in funding, as more orphan drugs come to the market. The Ministry of Health are adopting models based on clinical outcomes and cost-effectiveness resembling the existing models in Europe.
The biggest opportunity today is in the gene therapy area. Many diseases that have significant societal and economic burden today will soon be treated effectively. We strongly believe that healthcare providers will accommodate for such innovative and curative therapies in collaboration with the industry which is considering creative pricing and payment models.
3.
Picture
Karim and  with Co-founder and chairman, Kamel Ghammachi

What is your proudest moment in your career thus far?
I see my career as a journey with milestones on the way which makes it difficult to point a single moment out. Nevertheless, looking back I would say there are two events that I am particularly proud of namely, the day the first child was infused with Spinal muscular atrophy (SMA) gene therapy in the Middle East with the excitement and emotions of the family and the physicians and how much they valued the work done by Genpharm; and the cultural transformation I led at Merckserono making it at the time one of fastest growing companies in the region and recognised amongst the best work environments in the industry.
4.

​What and who are your personal and professional inspirations and why?
I am truly inspired by the work we are doing at Genpharm. Shedding light on the Middle East and the rare disease segment in the region has helped awareness and accelerated the access to the new class of therapies. While we were trying at first to convince multinational companies to consider the region, we have managed to partially reverse the situation with companies now initiating the contact to explore the Middle East opportunity.
​​
Furthermore, I have met many parents and families of children with rare disease. The dedication, commitment and the length at which these parents are willing to go to help their children is indescribable and extremely inspiring. It serves as motivation, but it also helps put life in perspective and make us realise how fortunate we are.
5.
What advice would you give someone considering working in the rare disease space?
Anyone interested in working in this space should always think Patient First. It might sound like a cliche but it’s true. This goes from the people in the lab to the field staff. One thing I learnt is that patience and perseverance are key ingredients to success. Things never happen as fast as we would like them to, particularly in the rare disease space. However, when working in the interest of the patient results tend to follow.
6.
​Do you think the government does enough for the rare disease community at a local and central level, and what gaps do you see currently or emerging?
Despite a lot of efforts, in particular in awareness, there are several areas that require additional investments and can be done through public private partnership (PPP) collaborations. For instance, several diseases that have effective treatments could be added to the newborn screening panels which remain mostly limited to a few haematological and metabolic disorders.
There is also a lack of national patient registries. Most are still hospital based with little exchange of information between hospitals. Registries are a very valuable resource to support clinical trials and/or publications on prevalence and incidence of disease which is challenging to obtain.
7.

​What would you say are some of the biggest motivators for your employees? 
I believe our employees are well aligned with our mantra and values. Bringing Cures to MENA patients is what we live by. The patient is always at the centre of our organisation. These are not merely slogans, but they are part of our culture. We bring a sense of urgency and a passion to what we do. Our employees are motivated by what Genpharm stands for and by their real ability to impact patient’s lives.
8.
Picture
Karim and Kamel
What are the toughest parts of being a CEO within Genpharm, and conversely what are the most rewarding? 
​Being a CEO in a company the size of Genpharm is both challenging and rewarding for the same reasons. You need to be involved deeply in both setting the strategic direction and in the daily operations. Having said this, being so close to the business allows you to have a direct impact on the development of the organisation. As the company grows, it is important to promote growth of staff and to have competent and trustworthy personnel to delegate to. We are fortunate to be in this situation today as we are developing a few employees to take on additional operational and management tasks.
9.

​What would be your one wish for Genpharm be for the year ahead?
​This year is turning out to be one of the most challenging in recent memory. With the current geopolitical situation in the region, the dramatic drop in oil prices, on which government budgets are built in the Gulf and the on-going global Coronavirus outbreak, we are indeed in crisis management mode. Nevertheless, we are still optimistic, and my wish would be to celebrate meeting our ambitious target by year end.
10.
​If you weren’t CEO of Genpharm what was Plan B?  What did your 10-year-old self, want to do as a job?
Since joining the industry, I always wanted to do something entrepreneurial. My education and the corporate world prepared me well for this endeavour by training me and helping me acquire management experience and expertise.
What is surprising is that growing up, I never thought of working in the healthcare or pharmaceutical sectors. Thinking of it now and how passionate I am about what we do, I couldn’t picture myself in any other industry. We are so fortunate to be able to reach and impact so many people lives in such a positive way.
To quote Confucius: Choose a job you love, and you will never have to work a day in your life.
Picture
To find out more about the work of Genpharm please visit
www.genpharmservices.com
0 Comments

David Jacob of ThinkGenetic

13/2/2020

0 Comments

 
Picture
Picture
Having achieved his dreams of becoming a Navy pilot and a professional bowler, it was personal circumstances that led David Jacob down a new path into the world of RARE, founding ThinkGenetic, which has become a true family affair
CEO Series: meeting the beating hearts behind the RARE brands
1.
What made you want to move into the wide world of rare disease, and then specifically ThinkGenetic and what did that journey look like?
The journey to ThinkGenetic and into the world of rare disease started for me at birth. My sister and I were both born with congenital heart defects that required open heart surgery as children. That was a big clue that our family journey had begun, but after recovering from the surgery, my parents didn’t mention it much and we just went on with our lives. That all changed when I turned 60 and had a severe case of pneumonia. As part of the diagnosis and monitoring, I had a chest x-ray and it incidentally found that I had a very large ascending aortic aneurysm. I asked my sister to have an echocardiogram and it was discovered she had the same aneurysm. 
By then, my eldest daughter had become a certified genetic counsellor. She recognised that the time had come for us to figure out the genetic basis of our health issues. She helped connect me with experts in connective tissue conditions related to heart defects and worked our way through several levels of genetic testing and analysis. After three long years, a lot of blood, and two analyses of my exome, we worked to narrow that down to a diagnosis:  Cutis Laxa – an ultra-rare genetic condition. 
After spending so many years wondering what it all meant and finally getting an answer, it was a little frustrating to find that there was very limited information for patients available on the condition. Something needed to change!  I decided that my mission was to help people living with or at risk to have a rare genetic condition have good access to accurate, patient-directed information to empower them and help reduce their time to finding a diagnosis and treatment. I knew that the solution was digital and by working with my long-term IT business partner, Len Barker, and my genetic-focused  daughter, we created ThinkGenetic with a goal of doing just that.
2.
What do you anticipate will be the biggest challenges and opportunities for your organisation in the next two years?
Our goal is to provide curated information on all 7,000+ known genetic conditions with appropriate next steps for diagnosis and treatment. We recently closed a $1.5 million seed round which has allowed us to cover 250 key conditions. We are starting a $5 million series A round which will allow us to meet this goal. As we add clients and patients, we want to scale ThinkGenetic worldwide to help undiagnosed patients discover genetic possibilities and next steps to shorten their diagnosis odyssey. We are currently receiving requests and activity from over 190 countries. Covering all genetic conditions and raising awareness on the internet to help undiagnosed patients will be our biggest challenge.
3.
What is your proudest moment in your career thus far?
I am fortunate to have lived a full life with an exciting career path that began with being a Navy pilot and then moved through the corporate world into my own company specializing in the development of individualized IT solutions in the rapidly changing world of IT. However, my proudest moments have been forming ThinkGenetic with my children to help others and as a family develop this very needed resource for people living with rare genetic conditions.
4.
Picture
The founders of ThinkGenetic
What and who are your personal and professional inspirations and why?
Treating others the way I would like to be treated has always been at the top of my list of inspiration and it still drives many aspects of my career. On a professional level, I learned how best to harness my competitive nature from my parents, how to treat others from my commanding officer at the Navy Test Pilot school, and in my business career from my 18-year association with Ross Perot at Electronic Data Systems (EDS).
5.
What advice would you give someone considering working in the rare disease space?
Many people are thrust into the rare disease space without getting to choose. If you are fortunate enough to choose entry, my advice is to listen to the patients, parents, and caregivers who have been there all along. You need their support to make a business work as much as they need yours to help raise awareness, learn about the conditions, and development therapies. Business in the rare disease space is a long-term commitment if you want to succeed; it’s not just about a special day of awareness or raising that first million dollars. It needs to be a passion to help the 280 million people worldwide who struggle each day to find treatments, funding and ongoing support.
6.
Do you think the government does enough for the rare disease community at a local and central level, and what gaps do you see currently or emerging?
In the US, healthcare, in general, is a for-profit business and leaves huge gaps in coverage for too many. I hope we can take the example of other progressive countries and make healthcare a right, not a privilege. I do admire the many groups like NORD, Genetic Alliance, and Global Genes, who continue to advocate on the Hill for rare patients to ensure there is access to expensive treatments. There have been some amazing milestones like the Orphan Drug Act and I hope to see continued support from our government.
7.
Dawn and David at the NORD awards
Picture
What would you say are some of the biggest motivators for your employees?
ThinkGenetic was founded by a unique combination of family and close friends whose members have personally seen the impact of living with a rare condition. We are all passionate about improving the time to diagnosis and treatment. Each team member, whether full-time staff, contractor, intern or volunteer has chosen to work in the rare disease space deliberately and work in education and advocacy space, even if it means long hours and low to no pay in some cases. Our mission is our biggest motivator because our successes have an impact well beyond a typical P&L [profit and loss] statement.
8.
What are the toughest parts of being a CEO, and conversely what are the most rewarding?
​As a CEO sometimes you have to make decisions that make sense to the overall company and board but are tough to execute. Deciding someone is not a good fit for a company when you’ve seen them invest blood, sweat and tears remains the most difficult part of the job. Sometimes you just wish the funding was never-ending and the personnel match was perfect – but that is not how business works.
​In addition, as someone working with family as well, I do my best to make sure every employee feels the connection to the business as we grow and becomes part of the ThinkGenetic family. I do have a unique situation because, in addition to the other team members, I do work directly with my incredible children who all have strengths and expertise in different areas. This means some days you’re a respected executive listening to important feedback and delegating key tasks, some days you’re getting kicked under the table for using the “wrong” wording, and some days you’re giving the 15-minute investment pitch. No matter the hat though, you’re always the dad. Keeping that separation between personal and professional is important but it does mean we discuss strategy over Christmas dinner.
9.
What would be your one wish for ThinkGenetic for the year ahead?
Like many start-ups we have too much to do and not enough time or funding. My wish is that the ThinkGenetic team continues to feel and see the positive impact of what we have accomplished and will accomplish in the rare disease space to change the world.
10.
If you weren’t CEO of Think Genetic what was Plan B?  What did your 10-year-old-self want to do as a job?
I’m way past Plan B. My 10-year-old self-wanted to be a professional bowler and astronaut. I did become a professional bowler and a Navy pilot so it was a good start.
​Once I was married and had a family, I gravitated to computer science and a career in this field – EDS, Data General, Davalen and finally ThinkGenetic. Over the past two decades I have been volunteering and advocating more in the rare disease and non-profit space. For example, I was a board member for Christopher’s Haven and Home Away Boston for many years until it was acquired by The Ronald McDonald House. If I wasn’t involved in ThinkGenetic, I think I would utilize my unique talents as a business owner and person living with a rare genetic disease to expand my role in rare disease space foundations and charities.
Picture
Picture

To find out more about the work of ThinkGenetic please visit
www.thinkgenetic.com

0 Comments

Becky Jenner of Rett UK

12/2/2020

0 Comments

 
Picture
Continuing in our CEO Series, Becky Jenner, CEO of Rett UK, shares her very personal journey that saw her give up a career in retail to co-found the charity Extratime and eventually become CEO of Rett UK

CEO Series: meeting the beating hearts behind the RARE brands
Picture
1.
What made you want to move into the wide world of rare disease, and then specifically Rett UK and what did that journey look like?
My career spans two halves really. Firstly in retail management starting as a Saturday assistant for Tesco, moving up to be an assistant manager with them and then with a company now called M & Co, initially as a store manager and then as an area manager, a post I returned to part time after having my first child Rosie … until D-day! D-day or diagnosis day was the day I found out my beautiful, smiley and happy fourteen-month-old had Rett syndrome, a rare, complex neurological disorder which mainly affects females. After a period of near-normal development up to the age of around one year to 18 months, the child regresses, in Rosie’s case overnight, losing key skills including the ability to walk, talk and have any purposeful hand use. With time, many medical comorbidities emerge including epilepsy, scoliosis, dystonia, gut and bowel dysfunction and severe breathing problems. To say life took a turn at that point is probably an understatement.

I resigned that day … I still remember saying hysterically to my boss at the time, ‘I will still be changing nappies when she is 30!’ Sounds ridiculous now! I spent the next few years concentrating on her, finding out how I could help her achieve the best she could and trying to find a way forward. I became a trustee of Rett UK, a post I held for 7 years, had two more children, did a business degree part time, then at the point when I wanted to return to work and found there was not any childcare available that would meet her needs (by now very complex) and that my two boys could go to too, I started a charity with a mum in a similar situation; Extratime has just celebrated its 15th year of providing inclusive after-school and holiday activities for children and young people aged 5-25 years.

When the vacancy of CEO at Rett UK came up, it was a natural step for me to combine my business, charity and personal experience … especially into something that I have such a personal investment in. That was in 2014, after 12 years at Extratime.
Picture
Celebrating 15 years of Extratime

Picture
2.
What do you anticipate will be the biggest challenges and opportunities for your organisation in the next two years?
The biggest challenges for us, like any small charity, is funding; finding new sources, making it go further but seeing demand for our services increase as cuts to statutory services that our families rely on continue to bite and cause them stress and hardship. We have worked hard to build alliances and partnerships where we can as we see the greatest opportunities here to ensure our families get the best we can offer them. We are a small community and we need to join with others to have a bigger voice and more influence about the things that matter to our families.
3.
What is your proudest moment in your career thus far?
I think that has to be winning Voluntary Sector Champion for Brighton and Hove in 2013, voted for by parents in the city and other professionals. It was fantastic to know how much people valued Extratime and what I had achieved with the team there.  
4.
What and who are your personal and professional inspirations and why?
​Rosie is my inspiration, my motivation and my drive every day to improve things for her and others affected by this devastating disorder. What she has to cope with on a daily basis is unimaginable for most people but she has an incredible zest for life, a wicked sense of humour and is the heart of our family. If she can keep going with what she has to deal with – anything I do is a walk in the park by comparison.
Picture
Becky with Rosie
5.
What advice would you give someone considering working in the rare disease space?
Do it! Especially if you are a medic or a researcher! We need more of you! We need new people to pick up the baton for rare diseases and take an interest in the research. There is a lot going on especially with gene editing and gene therapy – these are exciting times and there will be some life-changing treatments in the next few years.
6.
Do you think the government does enough for the rare disease community at a local and central level, and what gaps do you see currently or emerging?
I think things are improving with the combined efforts of the rare disease community but we need to keep the pressure on. Who knows with Brexit how that will affect the European playing field? A lot of research is done in Europe involving UK researchers and vice versa. How will those programmes be managed, funded? Will we lose some good people – probably! And at a time when so many advances are being made with gene therapies in particular, this is not great. The government nationally needs to ensure that this vital research is not compromised and also take a long term view that investment in rare diseases may be expensive initially but the longer term payback of getting the right treatment and therapies for this community is greater. Locally, our community is suffering because of the financial austerity which has decimated care and support services especially respite. Families crumble without regular breaks.
7.
What would you say are some of the biggest motivators for your employees?
Without doubt it is our families, their lives, their stories – our staff are moved every day by the challenges they face and they genuinely want to help make a difference. When they receive a thank-you card from someone, and they get a lot, they are so touched that they found the time to write it!
8.
What are the toughest parts of being a CEO, and conversely what are the most rewarding?
​The toughest part for me is dealing with the death of someone with Rett syndrome. I have been involved with Rett UK for over 22 years as a trustee, a family member and now CEO – many of my friend’s daughters have already passed. Of 7 girls that Rosie was at school with who had Rett syndrome only two are still alive. It is also hard for me to switch off as so much support and fundraising is now done on social media. The expectation of an instant response, especially outside of ‘normal’ work hours, is a real challenge for a small team working nationally so invariably that falls to me. The most rewarding is getting out of the office to meet the families at our events and seeing how much they value what we do. The feedback we get is fantastic!
Picture
9.
What would be your one wish for Rett UK for the year ahead?
That they run for government, sort Brexit out and put rare diseases at the heart of any plan.
10.
If you weren’t CEO of Rett UK, what was Plan B?  What did your 10-year-old self want to do as a job?
Plan B is to get a piece of land, grow beautifully scented British flowers to sell to anyone who appreciates them! My ten-year-old self wanted to do something that involved working outside but the only thing the ‘career advisor’ at the time could suggest was working for parks and gardens! My youngest son, now 18, has just completed the most amazing BTEC course in Adventure Sports – now he can go anywhere in the world teaching sailing, kayaking, mountain bike leading, climbing! How I would have loved to do that!
Picture
To find out more about the work of Rett UK please visit
www.rettuk.org

0 Comments

Sandy Royden of OPEN Health

15/7/2019

0 Comments

 
Picture
Picture
Second up in our ​brand new CEO Series is OPEN Health co-founder and COO, Sandy Royden. Sandy shares how she has been guiding the brands growth in the rare disease space and her aspirations for the future.

CEO Series: meeting the beating heart behind the RARE brands

1.

What made you want to move into the wide world of rare disease, and then specifically OPEN Health, and what did that journey look like?

Given my pharmacy background, I have always been interested in the pathophysiology of disease.   Rare Diseases therefore fascinate me – as they ’fall outside of the norm’ in terms of common ailments and conditions. I strive to understand their genetic links or inherent causes, and then thrive on the opportunity to help communicate and explain this to a wider audience – HCPs, patients, family and carers.   Being able to rationally explain a disease and potential treatment options, particularly in the rare disease space where their population rarely get any support, is hugely gratifying.   This personal interest is also reflected across OPEN Health, where there are a number of like-minded people with similar interests.   In particular, our director of rare disease, Gavin Jones, does a great job of really understanding the impact of a rare disease from a patient’s perspective, and communicating this across our business, so that we all share the same empathy, passion, and desire to have a positive impact on the treatment of these conditions.

2.

What do you anticipate will be the biggest challenges and opportunities for your organisation in the next two years?

​From a rare disease perspective, I think it is a case of constantly challenging ourselves to find innovative ways of supporting our customers.  The landscape is rapidly evolving with significantly different ways of treating patients very much on the near horizon.  You just have to look at the imminent introduction of gene therapies to see that healthcare communications and value recognition need to rapidly evolve.  I think it is exciting that rare disease could be seen as the platform to promote new relationships between the varying stakeholders in healthcare including patients and their advocacy groups.  We would like to be seen at the forefront of this new world and are busy working to create solutions to support improved communications and outcomes both now and long into the future.

3.

What is your proudest moment in your career thus far?

My proudest moments are when you actually hear about ‘real’ patients who have benefitted from the treatments we have worked on.  At the end of the day our goal is to ensure stakeholders are educated on relevant aspects, across a variety of different diseases and specific treatments, and that by effective communication initiatives we can optimise patient access to medicines.
 

4.

What and who are your personal and professional inspirations and why?

I take personal inspiration from Audrey Hepburn – there was nothing she couldn’t do -  she was a humanitarian, dancer, actress and member of the Dutch resistance.   What I take from her is ‘endless optimism’ –‘Nothing is impossible’ – in fact the word itself says I’m possible!
From a professional perspective,  with pharmacy at my core, I want to ensure we drive patient access to new and innovative medicines and technologies.

5.

What advice would you give someone considering working in the rare disease space?

​Whatever role you are considering playing in the rare disease community I would say go for it!  It is very fulfilling to work in this field and supporting improved outcomes where there is significant unmet need.  You will experience a close connection while making a difference for rare disease patients and their families.  Whatever role you are in, my advice is that you develop a clear mantra in what you are trying to achieve and the benefit this will have within the rare disease community.  By living and breathing this mission you will find that your voice will more likely be heard and you can have a greater impact.

6.

Do you think the government does enough for the rare disease community at a local and central level, and what gaps do you see currently or emerging?

I think one of the most concerning gaps is the challenge of gaining appropriate funding for the use of medicines and therapies in rare disease.  Given the numerous emerging new treatments and technologies there is rightfully a lot of hope within the rare disease community.  However, these medicines will often come with a high price tag and their value to health systems may not be realised for some time after they are introduced and initially used by patients.  This combined with health technology appraisals that are not best suited to assess value in rare disease and we have an issue.  This is playing out at the moment with a number of high-profile cases not gaining approval for use in various health systems.  We need to have more open dialogue across the different stakeholder groups in rare disease so we can ensure equitable access to the most effective treatments for patients.
Picture

7.

​What would you say are some of the biggest motivators for your employees?

​I believe our culture is something that is incredibly important to our employees.  We have a very diverse range of capabilities within our business and with that come wide ranging skill sets and personalities.  Collaboration is so important to us in enabling people to positively work together in supporting improved outcomes for our customers and the patients they are striving to serve.  Everyone in our business, from our creative directors to our admin staff, recognises that they all play a part in improving healthcare for patients which in turn motivates all of us to make every effort in making a difference.

8.

What are the toughest parts of being a CEO, and conversely what are the most rewarding?
​Being a CEO can be extremely rewarding  - particularly seeing and supporting people within our organisation to grow, develop and achieve their personal and professional aspirations.   But alongside that comes some of the tough decisions – reducing resources and cutting your cloth during the challenging times.

9.

What would be your one wish for OPEN Health for the year ahead?
​I would love to see OPEN Health continue to grow and further enhance our reputation in the rare diseases space.  I want us to be able to deliver truly innovative programmes that have a measurable and positive impact on patients’ lives.

10.

If you weren’t CEO of OPEN Health what was Plan B?  What did your 10-year-old-self want to do as a job?
​I always wanted to be a pharmacist, and once qualified and more experienced in the various career opportunities. I sought out a clear path through marketing and healthcare communications.  To be honest, if I had failed to achieve the grades to study for pharmacy, I was going to have a total career change and study hotel catering and management………who knows where that would have taken me!  
Picture
To find out more about the work of OPEN Health please visit www.openhealthgroup.com
0 Comments

Rick Thompson of FINDACURE

9/5/2019

0 Comments

 
Picture
Picture
We are thrilled to launch our ​brand new CEO Series with friend of the revolution, Rick Thompson, With a surprising journey from moles and dinosaur digging to CEO of the patient loved charity, Findacure, Rick Thompson shares his journey into rare disease and his hopes and challenges for the year ahead

CEO Series: meeting the beating heart behind the RARE brands

1.

What made you want to move into the wide world of rare disease, and then specifically Findacure and what did that journey look like?
​I’ve been into science for as long as I can remember, and really just followed my nose in my studies. I did a Biology degree, and ended up specialising in Zoology. From there I spent time at the Natural History Museum in London, before starting a PhD all about moles. Now, moles are truly fascinating animals, and studying to be a doctor (the useless kind) was a fantastic experience. But by the end of the five year period it dawned on me that very few people in the world really cared about my work. It would never make anyone’s life better, or richer. It was this realisation that drove me to look for work in the charity sector, applying my scientific background to the medical field.
The position at Findacure was a really exciting one – it offered me the chance to learn more about the biomedical field, while interacting first hand with people living with rare diseases – people who rarely get any support. This was a huge opportunity for me to make use of my studies in a meaningful setting, and when I was lucky enough to be offered the job I seized it with both hands.
I’m acutely conscious that the majority of people working in this field have personal experience of rare conditions – something that I fortunately do not have. There are times when I worry that this disconnect could limit my ability to connect with the patient experience; however, I also hope that it helps to keep Findacure from bias towards any one condition, and drives us to find and listen to as many patient stories as possible.

2.

What do you anticipate will be the biggest challenges and opportunities for your organisation in the next two years?
The biggest challenge for everyone in this sector is funding and sustainability. A huge priority for us right now is to secure more long-term funding so that we can plan our training programmes in a more strategic manner, and hopefully grow our activities so that they can benefit more organisations. We hope that this type of sustainability will allow us to dedicate more time to our beneficiaries, but also more time to partnerships. There are a number of fantastic cross-rare disease organisations out there, Rare Revolution and Medics4RareDiseases to name two, that I hope that Findacure can begin to work with more closely in the next few years. This will help to build a tighter and more unified rare disease community, help us all to share resources and expertise, and hopefully ensure the sustainability of all organisations. 

3.

What is your proudest moment in your career thus far?
​This is a tough question. I was obviously very proud to take over Findacure as CEO, and I am proud whenever I get to walk out on stage and talk about our work. My proudest moments though tend to be more related to the impact of our work – seeing the energy in the room at the end of our conference or workshops always fills me with a sense of pride and well-being. I was also particularly proud when my mentee Liz got up on stage and delivered her first ever presentation to a live audience at last year’s peer mentoring summer meet-up event. She did an amazing job, and it felt like a huge personal achievement for her, and a great tribute to all of her hard work.

4.

What and who are your personal and professional inspirations and why?
David Attenborough is a national treasure and a true hero. I saw him talk in person recently, and his delivery, humour, and desire to share science in an accessible way is absolutely priceless. His passion, dedication, and openness is something we can all aspire to. Professionally, there is no one inspiration, it is more the knowledge that nearly every patient group leader that I work with is doing a similar job to me while living with the impact of a rare condition. Their positivity, energy, and drive is inspiring and a lot to live up to!

5.

What advice would you give someone considering working in the rare disease space?
Talk to patients and talk to parents as often as you can. Never lose sight of the fact that they are the people that you are working to support, and their voice cannot be heard too frequently.

6.

Do you think the government does enough for the rare disease community at a local and central level, and what gaps do you see currently or emerging?
In a word, no. Fragmentation of any given rare disease patient population means that most fall through the cracks of local support – whether care for individuals, or for charities seeking funding. At the national level, aside from major concerns about the impact of leaving the European Union (I will not use that word…), there remain serious worries about how the NHS will find ways to pay for many of the new rare disease treatments on the horizon. While prices are high in many cases, it is crucial that companies also feel able to secure a return on their investment in rare diseases. If they cannot, we will see more and more companies moving out of orphan drug development. The government have to find a way to balance this very tough situation.

7.

What would you say are some of the biggest motivators for your employees? 
Without doubt the whole team are motivated by running events, and interacting with patients, carers, and charity professionals. We are part of a vibrant rare disease community, and love spending time hearing about all of their work, successes, challenges, and exceptional persistence.
Picture

8.

What are the toughest parts of being a CEO, and conversely what are the most rewarding? 
Another charity CEO told me that in our sector, CEO stands for Chief Everything Officer, and I think this nicely summarises the challenges and rewards of the role. As CEO of a small team my job is to steer the ship, and plug the holes. If anything goes wrong, it is my responsibility to fix it, and deliver the work as quickly and seamlessly as possible – whether I know what I am doing or not! This can lead to some stressful moments, but also some huge successes. Luckily for me I am supported by an exceptional team at Findacure, so most of the time I get to bask in the reflected glory of their success!

9.

What would be your one wish for Findacure for the year ahead?
The easy answer is a nice long-term sustainable source of funding – but this really goes without saying. Aside from this, I would like to see us gain recognition amongst the medical professionals who run rare disease specialist centres around the UK. This would give us fantastic connections with the UK’s rare disease specialists, but also help us to find more new founded patient groups, and more newly diagnosed patients seeking support.

10.

If you weren’t CEO of Findacure, what was Plan B?  What did 10-year-old Rick want to do as a job?
Well ten year old Rick probably wanted to be digging up dinosaurs. I never quite managed that, but I did something pretty close both by digging up 30 million year old fossil mammals in Spain, and writing a paper all about Ankylosaurs – so I certainly can’t complain! 
Picture
Picture
To find out more about the work of Findacure please visit
www.findacure.org.uk
0 Comments
Forward>>

    Author

    RARE Revolution on behalf of The Humans of RARE

    Archives

    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    February 2020
    July 2019
    May 2019

    Categories

    All

    RSS Feed

Rare Revolution is published by NRG Collective, a not-for-profit media company specialising in rare disease content
Contact Us
Editor:  
   editor@rarerevolutionmagazine.com
​Advertising: rstewart@rarerevolutionmagazine.com

  • Home
  • Rare Revolutionaries
    • Our Charity Partners
    • Revolutionaries Community
    • Join the Rare Revolution - Charities sign-up
    • Our Corporate Friends
  • Blog
  • Back Issues
  • #RareYouthProject
    • RYP Blog
  • The People of RARE
    • CEO Series
    • PEO Series
  • APP & Downloads
  • Media